Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Atlantica Sustainable Infrastructure

Brookfield Property Partners

Electronic Arts

Diamondback Energy

Freshpet

Lululemon Athletica

Middleby

SVB Financial Group

WD-40

When investors think of Nasdaq stocks to buy, they mostly gravitate to technology names. Here are 10 stocks that don't follow this trend.

10 Nasdaq Stocks to Buy and Hold for the Long Haul

The robotic-surgery leader is benefitting as its rivals falter.

Why Intuitive Surgical Stock Surged 20% in July

Intuitive Surgical’s stock lost more than 38% – dropping from $600 at the beginning of the year to below $370 in late March – then spiked 85% to around $680 now. That means it is well above the levels where it started the year.

Despite An 85% Rally Intuitive Surgical Stock Can Grow Further

Intuitive Surgical, Inc.'s (NASDAQ: ISRG) second-quarter report Tuesday was “surprisingly positive,” according to Canaccord Genuity.

Intuitive Surgical's Outlook 'Has Never Been Stronger,' Analyst Says After Q2 Report

Revenues and profits still fell significantly, however -- which was expected due to the coronavirus pandemic.

Intuitive Surgical Trounces Analysts' Q2 Estimates

DaVita

Medtronic

Owens & Minor

1Life Healthcare

Tandem Diabetes Care

Walgreens

With so much focus and attention geared toward the novel coronavirus and the COVID-19 pandemic, health care has been affected in many strange ways.

7 Post-Coronavirus Health Care Stocks That Will Win in the Years Ahead

Intuitive Surgical's (ISRG) second-quarter results reflect weak performance across all businesses and lower revenues.

Intuitive Surgical (ISRG) Q2 Earnings Top Estimates, Down Y/Y

Intuitive Surgical, Inc. (ISRG) CEO Gary Guthart on Q2 2020 Results - Earnings Call Transcript

Shares of Intuitive Surgical (NASDAQ:ISRG) increased 4.12%% in after-market trading after the company reported Q2 results.

Recap: Intuitive Surgical Q2 Earnings

Late Tuesday, Intuitive Surgical reported adjusted earnings of $1.11 per share on $852 million in sales for its second quarter ended June 30. In response, ISRG stock popped.

Robotic Surgery Leader Extends Breakout After Crushing Quarterly Estimates

Intuitive Surgical: Its Competitive Advantage Extended

With cases surging again, this company could be deeply affected.

The 1 Healthcare Stock to Buy If Coronavirus Fears Crash the Market Again

Moderna

Nasdaq Rises 29 as Intuitive Surgical Defies Robotic Surgery Competition; Moderna Jumps Again on Coronavirus Vaccine Prospects

Rivals are having trouble rolling out their robots.

Why Intuitive Surgical Stock Popped 8% on Friday

Intuitive Surgical's (ISRG) second-quarter earnings are likely to reflect weaker-than-expected performance at Instruments & Accessories segment and decline in da Vince procedure volume.

What's in the Cards for Intuitive Surgical (ISRG) Q2 Earnings?

Visa

These businesses are so outstanding that you'll never want to sell them.

Got $5,000? Here Are 3 Stocks to Buy and Never Sell

Incyte

Lockheed Martin

M/I Homes

Ocular Therapeutix

Cloud Charts Tell Me To Wait Until I See Sunshine

Stryker

Intuitive Surgical’s stock has rallied 56% since the March 23 lows, while Stryker stock has gained 41% of its value. The spread of Covid-19 in various parts of the world has had a negative impact on the medical devices industry globally, due to the postponement of elective surgeries.

Is Stryker A Better Buy Compared To Intuitive Surgical?

Abbott Labs

Shockwave Medical

Catalysts are potentially on the way for these leading medical device stocks.

3 Top Medical-Device Stocks to Buy in the Second Half of 2020

Amazon

Microsoft

Block

AT&T

Take control of your financial future by purchasing this perfect blend of growth and income stocks.

5 Top Stocks to Secure Your Financial Independence

Baxter

Boston Scientific

Hill-Rom Hlds

Perrigo

ResMed

Zimmer Biomet Hlds

Medical Products Industry's Near-Term Outlook Lacks Spark

Betting on these winners is a lot smarter than betting against them.

Have $5,000? Buy These 3 Practically Invincible Stocks

Kirkland Lake Gold

Palo Alto Networks

Pinterest

U.S. Bancorp

Buying great companies at a discount during periods of fear and panic can make you rich.

News for Intuitive Surgical Stock (ISRG)